Clinical Trial 43673

Tulsa, OK 74136


Summary:

A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis


Qualified Participants Must:

• Ages 12 to 17
• Onset of atopic dermatitis symptoms (eczema) for 3 years prior
• Must have legal guardian or representative willing to attend study visits


Qualified Participants May Receive:

May receive compensation for time and travel

All patient care is free of charge

Placebo or 15 mg Upadacitinib, taken orally

Placebo or 30 mg Upadacitinib, taken orally


Clinical trials are medical research studies designed to test the safety and/or effectiveness of new investigational drugs, devices, or treatments in humans. These studies are conducted worldwide for a range of conditions and illnesses. Learn more about clinical research and participating in a study at About Clinical Trials.